University of Bristol - Explore Bristol Research

Transcription

1 The Global BMI Mortality Collaboration, & Bansal, N. (06). Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 39 prospective studies in four continents. Lancet, 3(006), DOI: 0.06/S (6)3075- Publisher's PDF, also known as Version of record License (if available): CC BY-NC-ND Link to published version (if available): 0.06/S (6)3075- Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Elsevier at Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:

2 Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to:the Global BMI Mortality Collaboration. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 39 prospective studies in four continents. Lancet 06; published online July 3.

3 The Global BMI Mortality Collaboration: Body-mass index and all-cause mortality Individual-participant-data meta-analysis of 39 cohorts across four continents Contents list of supplementary material: CLICK on any item to jump to it Note: WHO defines 6 BMI groups (underweight, normal, overweight and grades I, II and III obesity). But, finer subdivision of the WHO normal and overweight groups yields the 9 finer groups used here. Supplementary Tables etable Pages no Baseline characteristics of the 39 prospective studies - Chronic diseases recorded at baseline in each study - Mortality outcomes and their ICD codes 6 BMI groups vs all mortality, by successively stricter inclusion criteria, in all 37 analysed studies 6 BMI groups vs all mortality, by successively stricter inclusion criteria, in 9 fully included studies 6 BMI groups vs all mortality, by smoking status 6 BMI groups vs all mortality, using standard CIs (rather than floating absolute risks) 9 BMI groups vs all mortality, by geographic region 6 BMI groups vs all mortality, by geographic region 6 BMI groups vs all mortality, by geographic region and sex 6 BMI groups vs all mortality, by geographic region and baseline age - Population-attributable fractions for overweight and obesity - Steepness of BMI vs all mortality for BMI>5 kg/m, by age and sex - Steepness of BMI vs CAUSE-SPECIFIC mortality for BMI>5 kg/m, by geographic region 9 BMI groups vs CAUSE-SPECIFIC mortality, by geographic region 6 BMI groups vs CAUSE-SPECIFIC mortality, by geographic region 9 BMI groups vs all mortality, (a) by fixed-effect methods and (b) in years 5-5 only 6 BMI groups vs all mortality, (a) by fixed-effect methods and (b) in years 5-5 only 6 BMI groups vs all mortality, effects of adjustment for race, or exclusion of baseline diabetes 6 BMI groups vs all mortality, by completeness of data on chronic diseases at baseline 6 BMI groups vs all mortality, by year of baseline survey 6 BMI groups vs all mortality, by method of assessing BMI 6 BMI groups vs all mortality, by occupational/other population source Supplementary Figures Pages efigure no Flow diagram of literature search Supplementary Appendices eappendix Pages no. 9 BMI groups vs all mortality, by baseline age and geographic region 9 BMI groups vs all mortality, by sex and geographic region 9 BMI groups vs all mortality, by sex and geographic region in studies with both men and women 9 BMI groups vs CAUSE-SPECIFIC mortality, by geographic region 9 BMI groups vs all mortality, by successively stricter inclusion criteria 9 BMI groups vs all mortality, by age at risk 9 BMI groups vs all mortality, absolute risks corresponding to the overall relative risks - Steepness of BMI vs all mortality for BMI>5 kg/m in each study, plotted vs mean BMI in that study - Steepness of BMI vs all mortality for BMI>5 kg/m in each study, plotted vs year of baseline survey - Steepness of BMI vs all mortality for BMI>5 kg/m in each study, plotted vs size of that study Investigators in each study Pre-specified analysis plan PRISMA-IPD checklist Systematic literature search procedures References Text-figures -

4 etable : Baseline characteristics of participating studies Study Ref Country Population source Weight & height assessment Total participants Mean (SD) BMI Mean (SD) age at survey Mean (SD) age at death No (%) males No (%) current smokers Median baseline survey year Median (IQR) follow-up time Death ascertain ment All-cause mortality CVD Number of deaths CHD Stroke Cancer Respiratory disease Europe Vorarlberg Health Monitoring and Promotion Programme Austria Health check-up measured (.) 7.9 (3.6) 70.0 (.0) 559 (6) 6 (9) 9 3. (.9, 5.6) Belgian Inter-university Research on Nutrition and Health Belgium Electoral roll measured (.). (3.3) 6.0 (0.0) 50 (53) 367 (33) (0.5, 0.5) Flemish Study on Environment, Genes and Health (FLEMENGHO) 3 Belgium General popln. measured (.3) 7.9 (5.9) 73.0 (.0) 656 (9) 90 (37) (6.5, 9.5) Seven Countries Croatia Croatia General popln. measured (3.3) 50.3 (5.) 67.0 (.0) 39 (00) 79 (59) (.5,.5) Copenhagen City Heart Study 5 Denmark Popln. register measured (.) 5.6 (.0) 70.0 (0.0) 65 (6) 37 (59) (.5, 7.5) Research Centre for Prevention and Health (Glostrup Population Studies) 6 Denmark Popln. register measured (.0). (3.6) 69.0 (3.0) 5076 (50) 5 (5) (5.5, 0.5) Finnish Mobile Clinic Survey 7 Finland General popln. measured (.0). (5.0) 70.0 (3.0) 03 (5) 9 (33) (0.5, 3.5) Finrisk Cohort 977 Finland Popln. register measured 00 6.(.) 3.7(0.9) 6.0 (0.0) 599 (9) 36 (30) (7.0, 7.0) Finrisk Cohort 9 Finland Popln. register measured (.3) 3.9(.3) 60.0 (9.0) 577 (9) 95 (3) 9.0 (.0,.0) Finrisk Cohort 97 Finland Popln. register measured (.).3(.3) 5.0 (9.0) 99 () 75 () (7.0, 7.0) Finrisk Cohort 99 Finland Popln. register measured (.5).9 (.) 6.0 (.0) 37 (7) (3) (6., 6.9) Finrisk Cohort 997 Finland Popln. register measured (.5) 9. (.3) 6.0 (9.0) 39 (50) 976 (6) 997. (.,.9) Helsinki Aging Study 9 Finland Popln. register measured (.) 7. (.) 5.0 (5.0) 3 (6) 37 () (.7,.0) Helsinki Businessmen Study 0 Finland Health check-up measured (3.0) 59. (.) 76.0 (7.0) 367 (00) 36 (7) 96.5 (.0,.5) Kuopio Ischaemic Heart Disease Study Finland Popln. register measured (3.6) 53. (5.) 67.0 (7.0) 655 (00) (3) 96.6 (., 3.6) North Karelia Project Finland Popln. register measured (.) 0. (9.9) 6(0) 553 (9) 397 (35) 97.0 (.0,.0) Seven Countries Finland Finland General popln. measured (3.) 9.3 (5.6) 65.0 (.0) 633 (00) 0 (63) (.5, 5.5) Centre d'investigations Preventives et Cliniques (IPC), Paris 3 France Health check-up measured (3.5) 0.7 (.7) 6.0 (.0) 93 (57) 653 (30) 9.5 (9.5,.5) Data from an Epidemiological Study on the Insulin Resistance Syndrome France Health check-up measured (3.) 7. (0.0) 6.0 (9.0) 55 (9) 7 () 995. (.,.7) Paris Prospective Study I 5 France Occupational measured (3.3) 7. (.0) 6.0 (7.0) 759 (00) 560 (7) (.5,.5) Prospective Epidemiological Study of Myocardial Infarction 6 France / NI General popln. measured (3.5) 5.9 (.9) 59.0 (3.0) 059 (00) 6 (7) (5., 6.) Epidemiologische Studie zu Chancen der Verhütung 7 Germany Health check-up measured (.3) 6. (6.6) 6.0 (6.0) 3 (5) 56 (7) (.9, 5.) Göttingen Risk Incidence and Prevalence Study Germany Occupational measured (3.0) 7.9 (5.) 56.0 (6.0) 5996 (00) 3 (37) 9 9. (9.7, 9.9) MONICA/KORA Augsburg Survey 9 Germany Popln. register measured (3.3) 5. (5.) 65.0 (7.0) 9 (00) 307 (33) (., 3.) MONICA/KORA Augsburg Survey 9 Germany Popln. register measured 3 7. (.) 53.3 (.) 6.0 (.0) 076 (50) 00 () (7.7,.) MONICA/KORA Augsburg Survey 3 9 Germany Popln. register measured (.5) 50. (3.7) 7.0 (0.0) 36 (9) 7 (5) (3.3,.3) Prospective Cardiovascular Münster Study 0 Germany Occupational measured (3.5) 3.9 (9.7) 6.0 (9.0) 0 (73) 7937 (39) (7., 7.) Study of Health in Pomerania Germany Popln. register measured (.7) 53. (.) 75.0 (0.0) 56 (9) 090 (9) (0.6,.) Württemberg Construction Workers Cohort Germany Occupational measured (3.6). (0.) 6.0 (6.0) 7 (00) 93 (53) (5.0,.6) ATTICA Study 3 Greece General popln. measured (.) 5. (0.9) 7.0 (3.0) 7 (5) 603 (39) (5.0, 5.0) Seven Countries Greece Greece General popln. measured (3.3) 9.3 (5.6) 6.0 (.0) 03 (00) 70 (60) (.5,.5) Notes are at the end of etable, on page 0. 3

5 etable (continued) Study Ref Country Population source Weight & height assessment Total participants Mean (SD) BMI Mean (SD) age at survey Mean (SD) age at death No (%) males No (%) current smokers Median baseline survey year Median (IQR) follow-up time Death ascertain ment All-cause mortality CVD Number of deaths CHD Stroke Cancer Respiratory disease Reykjavik Study Iceland Popln. register measured (3.9) 5. (.) 76.0 (0.0) 909 () 7 (7) (.7, 33.) Bezafibrate Infarction Prevention Registry Study 5 Israel GP list measured (3.) 60. (7.0) 67.0 (7.0) 565 (9) 730 () (0., 7.5) Israeli Ischaemic Heart Disease Study 6 Israel Occupational measured (3.3) 9.3 (6.9) 6.0 (9.0) 0033 (00) 506 (50) (9.5, 3.5) Glucose Intolerance, Obesity and Hypertension Study 7 Israel Popln. register measured (.) 3.5 (.5) 70.0 (0.0) 699 (9) 735 (3) (5.9, 36.0) Bruneck Study Italy Popln. register measured 99.9 (3.) 5.9 (.5) 7.0 (0.0) 67 (5) () (3.7, 0.5) Cardiovascular Study in the Elderly 9 Italy Popln. register measured (.3) 73.6 (5.).0 (6.0) 57 (39) 6 (3) 9. (6.,.7) Occupational Groups (OG), Rome 30 Italy Occupational measured (3.3) 55. (5.3) 6.0 (6.0) 33 (00) 67 (50) (9.5, 0.5) Progetto CUORE (ATENA) 3 Italy Electoral roll measured (.) 50.0 (7.) 59.0 (9.0) 0 (0) 977 (0) (6.0, 7.5) Progetto CUORE (EMOFRI) 3 Italy Electoral roll measured (.) 5.7 (5.7) 59.0 (.0) 00 (50) 06 (7) (6.6, 7.0) Progetto CUORE (MATISS3) 3 Italy Electoral roll measured 67. (.5) 5. (9.6) 70.0 (9.0) 60 (7) 75 (9) 9.7 (.5,.9) Progetto CUORE (MATISS7) 3 Italy Electoral roll measured 0.7 (.5) 5.6 (9.5) 6.0 (.0) 9 () 7 () (5., 5.9) Progetto CUORE (MATISS93) 3 Italy Electoral roll measured 30. (.6) 9. (9.3) 6.0 (.0) 63 () 3 (6) 99.3 (7., 9.) Progetto CUORE (MONFRI6) 3 Italy Electoral roll measured 6.6 (.) 9.3 (.7) 65.0 (.0) 7 (9) 59 (3) (6.6, 6.) Progetto CUORE (MONFRI9) 3 Italy Electoral roll measured (.3).7 (.3) 6.0 (9.0) 69 (50) 39 () (3.5, 3.6) Progetto CUORE (MONFRI9) 3 Italy Electoral roll measured (.3) 9. (.) 59.0 (6.0) 60 (50) 365 (7) 99.5 (.3,.6) Risk Factors and Life Expectancy Pooling Project (ATS_SAR) 3 Italy Electoral roll measured (.5) 6.3 (7.) 5.0 (6.0) 00 () 0 (3) 93.7 (7.7,.7) Risk Factors and Life Expectancy Pooling Project (DISCO) 3 Italy Electoral roll measured 06. (.6) 50.6 (.) 66.0 (7.0) 9 () 539 () (5.5,.5) Risk Factors and Life Expectancy Pooling Project (GREPCO) 3 Italy Electoral roll measured (3.9) 3.9 (.3) 5.0 (9.0) 0 (0) 39 () (7.,.) Risk Factors and Life Expectancy Pooling Project (GUBBIO) 3 Italy Electoral roll measured (.) 55.0 (3.) 73.0 (0.0) 55 () 6 (3) 9. (7., 9.) Risk Factors and Life Expectancy Pooling Project (MICOL) 3 Italy Electoral roll measured (.0) 50. (9.7) 6.0 (.0) (56) 67 (3) (5.5, 6.) Risk Factors and Life Expectancy Pooling Project (MONICA) 3 Italy Electoral roll measured (.) 9.3 (9.0) 59.0 (.0) 30 (50) (3) (.3,.5) Risk Factors and Life Expectancy Pooling Project (NFR) 3 Italy Electoral roll measured (3.3) 55. (5.3) 6.0 (6.0) 3339 (00) 67 (50) (9., 0.) Risk Factors and Life Expectancy Pooling Project (OB3) 3 Italy Electoral roll measured (.) 7.0 (7.) 57.0 (6.0) 793 () 90 (36) (5.,.) Risk Factors and Life Expectancy Pooling Project (RF) 3 Italy Electoral roll measured (.3). (9.3) 59.0 (7.0) 603 (7) 006 (36) (., 3.) Seven Countries Italy Italy Occupational measured (3.).7 (5.) 66.0 (.0) 60 (00) 53 (6) (6.5,.5) Vicenza Thrombophilia and Athrosclerosis Project 33 Italy Census list measured (.0) 5. (.) 73.0 (.0) 77 (6) 5 (6) (.3,.) Consultation Bureau Project 3 Netherlands General popln. measured 9.6 (3.) 3. (.3) 50.0 (6.0) 3330 () 507 (5) (0.5, 3.5) Hoorn Study 35 Netherlands Popln. register measured (3.6) 6.7 (7.3) 7.0 (.0) 30 (6) 767 (3) (.,.) Longitudinal Aging Study Amsterdam 36 Netherlands Popln. register measured (.) 70. (.7).0 (7.0) 77 (9) 657 (5) (6., 0.) Monitoring of CVD Risk Factors Project 37 Netherlands General popln. measured 3 5. (.0). (0.3) 6.0 (.0) 60 (7) 090 () (5.,.0) Prevention of Renal and Vascular End Stage Disease Study 3 Netherlands General popln. measured 6. (.) 9.3 (.7) 7.0 (0.0) (50) 90 (3) 99.7 (.,.9) Notes are at the end of etable, on page 0.

6 etable (continued) Study Ref Country Population source Weight & height assessment Total participants Mean (SD) BMI Mean (SD) age at survey Mean (SD) age at death Seven Countries Netherlands Netherlands General popln. measured 76.0 (.7) 9. (5.5) 67.0 (.0) 76 (00) 65 (7) (7.5,.5) The Rotterdam Study 39 Netherlands Popln. register measured (3.7) 6.7 (.).0 (.0) 60 () 6 (0) 99.9 (.9,.9) The Rotterdam Study II 39 Netherlands Popln. register measured (.) 6.6 (7.7) 77.0 (9.0) 00 (5) 60 (3) (9., 0.5) The Rotterdam Study III 39 Netherlands Popln. register measured (.6) 56.9 (6.) 65.0 (0.0) 5 (3) 960 (7) (.,.) Cohort of Norway (FINNMARK) 0 Norway Popln. register measured (.5) 59.9 (9.9) 7.0 (.0) 97 () 3 (36) (7.5, 7.5) Cohort of Norway (HUBRO) 0 Norway Popln. register measured (.) 5.0 (.) 75.0 (0.0) 7 (5) 66 () 00.5 (.5, 9.5) Cohort of Norway (OPPHED) 0 Norway Popln. register measured (.) 53. (.7) 7.0 (.0) 739 (6) 33 (3) 00.5 (.5,.5) Cohort of Norway (OSLO) 0 Norway General popln. measured (3.) 69. (6.3) 77.0 (5.0) 633 (00) 355 () (9.5, 9.5) Cohort of Norway (TROMS) 0 Norway Popln. register measured (.) 5. (.) 67.0 (7.0) 950 (5) 75 (3) (7.5, 7.5) Norwegian Counties Study (NCS) Norway Popln. register measured (3.5). (.3) 5.0 (6.0) 9 (50) 0650 (3) (5.7, 6.) Norwegian Counties Study (NCS) Norway Popln. register measured (3.).3 (.) 55.0 (6.0) 69 (5) 567 (39) (7.0, 7.6) Norwegian Counties Study (NCS3) Norway Popln. register measured (3.). (.) 55.0 (6.0) 5 (5) 56 (56) 97. (.0,.) Oslo Study Norway Popln. register measured (.9) 3.9 (5.6) 66.0 (.0) 776 (00) 9937 (56) (5., 30.0) Tromsø Study 3 Norway Household listings measured 60. (3.7).9 (5.6) 7.0 (0.0) 00 (7) 0607 () 97.9 (3.9,.) Edinburgh Artery Study Scotland GP list measured (3.9) 6.9 (5.7) 7.0 (7.0) 0 (5) 03 (5) 9. (0.5, 0.) Prospective Study of Pravastatin in the Scotland/Ireland/ 5 Elderly at Risk Netherland Health check-up measured (.) 75.3 (3.3) 7.0 (.0) 0 () 557 (7) (3.0, 3.5) Seven Countries Serbia Serbia Occupational measured 56.5 (3.6). (5.9) 66.0 (.0) 56 (00) 0 (5) (7.5, 5.5) Diet and Risk of Cardiovascular Disease in Spain 6 Spain General popln. measured (.) 39.5 (.5) 6.0 (9.0) 50 () () (.9, 9.5) Zaragoza study 7 Spain Popln. register measured 37. (5.0) 5.9 (.7) 6.0 (5.0) 75 () 70 () (5., 5.) Apolipoprotein Related Mortality Risk Study Sweden Health check-up measured (3.7) 5.9 (0.) 66.0 (.0) 3396 (5) NA (0., 5.3) Cohort of Swedish Men 9 Sweden Popln. register self-reported (3.) 60.0 (9.7) 73.7 (.0) 357 (00) 09 (5) (0.0, 0.0) Göteborg 93 Study 50 Sweden Popln. register measured (3.) 5. (.) 7.0 (.0) 79 (00) 3 (5) (7., 30.5) Göteborg 933 Study 50 Sweden Popln. register measured (3.) 50.6 (0.) 5.0 (.0) 753 (00) 69 (36) 9. (.7, 3.0) Göteborg 93 Study 50 Sweden Popln. register measured (3.) 50.0 (0.0) 56.0 (3.0) 793 (00) (3) (9., 0.6) MONICA Göteborg Study 9 Sweden Popln. register measured (3.9) 7.0 (0.6) 65.0 (9.0) 060 () 59 (30) (.9, 7.7) Malmö Prevention Project 5 Sweden Popln. screening measured (3.6) 5.7 (7.) 69.0 (9.0) 99 (67) 50 (5) (3.9, 3.) Prospective Study of Women in Gothenburg 5 Sweden Popln. register measured 60. (3.) 6.9 (6.3) 77.0 (0.0) 0 (0) 593 () (7., 0.7) Swedish Mammography Cohort 53 Sweden Popln. register self-reported (.0) 6.7 (9.) 7.3 (.0) 0 (0) 0 (3) (0.0, 0.0) Uppsala Longitudinal Study of Adult Men 5 Sweden General popln. measured (3.) 9.6 (0.6) 76.0 (.0) 3 (00) 77 (6) (., 36.) Women's Lifestyle and Health Study 55 Sweden Popln. register self-reported (3.6) 0. (5.) 5. (6.6) 0 (0) 00 () (.0, 5.0) Turkish Adult Risk Factor Study 56 Turkey Household listings measured (5.).5 (3.7) 70.0 (.0) 7 (50) 366 (36) (., 0.0) British Regional Heart Study 57 UK GP list measured (3.) 50. (5.) 6.0 (.0) 779 (00) 50 (5) (9.,.9) British Union Provident Association Study 5 UK GP list measured (.) 7.5 (7.7) 6.0 (9.0) 50 (00) 7 (39) (., 5.) No (%) males No (%) current smokers Median baseline survey year Median (IQR) follow-up time Death ascertain ment All-cause mortality CVD Number of deaths CHD Stroke Cancer Respiratory disease British Women's Heart and Health Study 59 UK Popln. register measured (5.0) 6. (5.5) 7.0 (6.0) 0 (0) 5 () (0.,.5) Caerphilly Prospective Study 60 UK Electoral roll measured 7 6. (3.6) 5. (.5) 6.0 (5.0) 7 (00) 370 (55) (3.0, 3.0) Hertfordshire Cohort Study 6 UK General popln. measured (.) 66. (.9) 7.0 (.0) 57 (53) 37 (3) 00.9 (7., 9.9) Notes are at the end of etable, on page 0. 5

7 etable (continued) Study Ref Country Population source Weight & height assessment Total participants Mean (SD) BMI Mean (SD) age at survey Mean (SD) age at death Lower Extremity Arterial Disease Event Reduction Trial 6 UK Popln. register measured 5 6. (3.) 6. (.7) 7.0 (.0) 5 (00) 57 (3) 997. (3.5,.9) Midspan Family Study 63 UK General popln. measured (.6) 5. (6.) 5.0 (7.0) 039 (5) 5 (5) (5., 5.6) The Million Women Study 6 UK Popln. screening self-reported (.7) 56. (.6) 67. (6.) 0 (0) 6637 () (3.,.) MRC Study of Older People 65 UK GP list measured (.3) 0. (3.7) 6.0 (5.0) 59 (0) 57 () 996. (.3, 0.5) Midspan Collaborative Study 66 UK Occupational measured (3.) 7.5 (7.) 65.0 (.0) 599 (6) 39 (56) 97.5 (0.5, 3.5) Northwick Park Heart Study I 67 UK Occupational measured (3.0) 5.5 (6.7) 7.0 (.0) 50 (00) 77 (5) (., 6.) Northwick Park Heart Study II 67 UK GP list measured (3.5) 56.6 (3.5) 66.0 (5.0) 303 (00) (37) 99. (7., 9.0) Renfew and Paisley Study 6 UK General popln. measured (.0) 5.3 (5.6) 66.0 (7.0) 705 (6) 7 (5) (5.5, 7.5) Scottish Heart Health Study 60 UK GP list measured (.) 50. (.) 6.0 (.0) 500 (9) 77 (5) (0.0, 0.0) Speedwell Study 69 UK GP list measured (3.3) 5.9 (.) 66.0 (6.0) 70 (00) 06 (7) (5., 7.7) Thrombosis Prevention Trial 70 UK GP list measured (3.5) 56.0 (6.) 67.0 (7.0) 7 (00) 79 (3) 990. (0.,.) UK Biobank 7 UK General popln. measured (.) 57.(.0) 6.5 (6.9) 757(6) 55() 009. (., 5.5) United Kingdom Heart Disease Prevention Project 7 UK Occupational measured (3.) 50.7 (5.7) 66.0 (.0) 36 (00) 656 (7) (7.5, 3.5) West of Scotland Coronary Prevention Study 73 UK Popln. screening measured (3.) 55. (5.5) 67.0 (0.0) 6595 (00) 907 () 990. (.3, 5.3) Whitehall I Study 7 UK Occupational measured 63.7 (3.0) 5.6 (6.7) 65.0 (7.0) 63 (00) 755 () (5.5, 5.5) Whitehall II Study 75 UK Occupational measured (3.5) 5.0 (6.) 3.0 (5.0) 60 (67) 67 (6) (6.9,.3) European Prospective Investigation into Cancer and Nutrition 76 Europe General popln.** measured (.3) 5.7 (0.) 6. (0.5) 939 (35) 9696 (7) (.5,.0) Subtotal (5 studies) (3.9) 5. (.) 67. (.0) 369 (33.5) 69 (3.) 97*.6 (., 3.7) No (%) males No (%) current smokers Median baseline survey year Median (IQR) follow-up time Death ascertain ment All-cause mortality CVD Number of deaths CHD Stroke Cancer Respiratory disease North America Nova Scotia Health Survey 77 Canada GP list measured 7.5 (5.3) 55. (5.5) 7.0 (0.0) 9 (9) 9 (7) (9.5, 9.9) Quebec Cardiovascular Study 7 Canada Popln. register measured (3.) 9.5 (.3) 6.0 (9.0) 00 (00) 00 (59) 97. (9.0, 7.) Agricultural Health Study 79 USA Occupational self-reported (.5) 7.3 (.5) 67.6 (.0) 06 (5) 6 (3) (9.0,.0) Air Force/Texas Coronary Atherosclerosis Prevention Study 0 USA Popln. screening measured (3.) 5. (7.) 66.0 (7.0) 560 (5) 65 () (., 5.9) NIH-AARP Diet and Health Study USA Popln. register self-reported (.) 6. (5.) 69. (5.) (60) 653 () (9.0, 0.0) Atherosclerosis Risk in Communities Study USA Household listings measured (5.) 5.7 (5.) 66.0 (7.0) 7055 (5) 506 (9) 9. (3.3,.9) Breast Cancer Detection Demonstration Project 3 USA Popln. screening self-reported (.6) 6. (.0) 7.3 (7.) 0 (0) 5 (3) (.0,.0) CLUE II USA Popln. register self-reported (.) 5.3 (.9) 7.7 (0.3) 935 () 3599 (7) 99.0 (0.0, 7.0) California Teachers Study 5 USA Occupational self-reported 33.9 (5.) 5.7 (3.) 7.7 (0.) 0 (0) 63 (5) (9.0, 9.0) Cancer Prevention Study I 6 USA General popln. self-reported (3.) 5.7 (0.5) 69.6 (.) 7509 (3) 906 (36) (.9,.9) Cancer Prevention Study II 6 USA General popln. self-reported (.) 56. (0.6) 79.0 (0.) 3679 (3) 537 () 9. (7.,.3) Cardiovascular Health Study (CHS) 7 USA Health insurance list measured (.5) 7.7 (5.3) 3.0 (6.0) 5 (3) 59 () (.0, 5.) Cardiovascular Health Study (CHS) 7 USA Health insurance list measured (5.6) 7. (5.5).0 (6.0) 5 (37) 99 (5) 993. (7.7,.) Charleston Heart Study USA Household listings measured 5 5. (.9) 50. (.) 7.0 (.0) 065 (7) 6 (55) (.6, 37.9) Chicago Heart Association Detection Project In Industry 9 USA Occupational measured (.) 0.7 (.) 7.0 (.0) 99 (5) () (., 33.) Established Populations for the Epidemiologic Study of the Elderly - East Boston 90 USA Popln. register self-reported (.) 77. (.).0 (5.0) 3 (37) 5 () 9.9 (.6, 5.3) Notes are at the end of etable, on page 0. 6

8 etable (continued) Study Ref Country Population source Weight & height assessment Established Populations for the Epidemiologic Study of the Elderly - Iowa 90 USA Popln. register measured (.6) 7. (.).0 (6.0) 63 (35) (5) (5.5, 5.) Established Populations for the Epidemiologic Study of the Elderly - New 90 USA Popln. register self-reported (.6) 77.9 (.).0 (5.0) 36 () (3) 9.3 (.0,.5) Haven Established Populations for the Epidemiologic Study of the Elderly - North 90 USA Popln. register self-reported (5.3) 77. (.7) 5.0 (6.0) 59 (36) 06 () (6.,.) Carolina Framingham Offspring Study 9 USA measured (5.0) 5. (9.7) 70.0 (9.0) 57 (6) () 99. (., 3.) Health Professionals Follow-up Study 9 USA Occupational self-reported (3.) 5. (9.9) 77.0 (0.0) 503 (00) 799 (0) (7., 0.3) Honolulu Heart Program 93 USA Military service registration list measured (3.) 5. (5.6) 73.0 (9.0) 7997 (00) 397 () (9.5,.5) Iowa Women's Health Study 9 USA Driver's license register self-reported (.9) 6. (.) 7.5 (6.) 0 (0) 653 (5) (6.0, 9.0) Lipid Research Clinics Follow-up Study 95 USA Health check-up measured (.3) 7.0 (.) 69.0 (.0) 69 (53) 37 (35) (7.5, 9.5) Minnesota Heart Health Project 96 USA General popln. measured (.) 5. (.5) 67.0 (.0) 7 (6) 55 (9) (3.5,.5) Minnesota Heart Survey 97 USA General popln. measured (.9).6 (3.) 65.0 (0.0) 66 (7) 59 (9) 95.5 (3.5,.5) Multi-Ethnic Study of Atherosclerosis 9 USA General popln. measured (5.5) 6. (0.) 75.0 (0.0) 305 (7) 05 (5) 00.6 (.,.6) Multiple Risk Factor Intervention Trial 99 USA Popln. screening measured (3.) 6.6 (6.0) 56.0 (6.0) 37 (00) 37 (6) 97.3 (0.,.7) NHLBI Framingham Heart Study 00 USA General popln. measured (.).0 (.6) 73.0 (.0) 33 (5) 90 (57) (.5, 39.5) NYU Women's Health Study 0 USA Occupational self-reported 05.9 (.6) 50. (.7) 6. (9.) 0 (0) () (7.0, 0.0) National Health and Nutrition Examination Survey I 0 USA Census list measured (5.) 9.0 (5.6) 7.0 (.0) 505 (0) 535 (37) 97.5 (3.5, 9.5) National Health and Nutrition Examination Survey III 03 USA Census list measured (5.) 5.3 (.3) 7.0 (.0) 77 (7) 37 (7) 990. (.3, 6.) National Health Interview Survey 0 USA Census list self-reported (5.7) 7.5(7.5) 7.6 (.) () 030 () 00 (3, ) Nurses' Health Study I 05 USA Occupational self-reported (.).6 (7.) 69.0 (0.0) 0 (0) (33) (.5,.9) Nurses' Health Study II 06 USA Occupational self-reported (5.3) 36.0 (.).7 (6.) 0 (0) 90 (0) (6.0, 6.0) Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial 07 USA Occupational self-reported (.9) 6.6 (5.) 7.7 (6.) 795 (9) 563 () (7.0, 0.0) Physicians' Health Study I & II 0 USA Occupational self-reported (3.0) 5. (9.) 7.5 (.6) 60 (00) 63 (9) 9.0 (7.0, 3.0) Puerto Rico Heart Health Program 09 USA Census list measured (.) 5. (6.6) 65.0 (7.0) 9799 (00) 575 (53) (.0,.0) Rancho Bernardo Study 0 USA Household listings measured (3.) 57. (5.0) 79.0 (9.0) 90 (6) 37 () 97.5 (3.5, 9.5) Seven Countries US USA Occupational measured (3.) 9. (5.) 77.0 (7.0) 556 (00) 507 (59) (6.0, 5.0) Seventh-day Adventist Cohort Study USA Census list self-reported (.3) 5. (5.5) 7. (9.9) 5 () () (0.0,.0) Strong Heart Study USA Tribal rolls measured (6.) 56. (.) 66.0 (9.0) 739 (0) (33) (0.0, 3.6) Tecumseh Study 3 USA General popln. measured 6 5. (.7) 7. (.) 7.0 (.0) 5 (9) 96 () (7.5, 6.5) U.S. Radiologic Technologists (URST) Cohort USA Occupational self-reported (5.0).9 (9.5) 63.7 (.) 09 (3) 7 () (.0, 6.0) Vitamins and Lifestyle (VITAL) Study 5 USA Popln. register self-reported (5.) 6. (7.) 70.0 (7.) 3570 (9) 605 () (5.0, 6.0) Women's Health Initiative (Observational Study) 6 USA General popln. measured (5.7) 63.6 (7.) 6.0 (.0) 0 (0) 566 (6) (., 3.) Women's Health Study 7 USA Occupational self-reported (5.) 5.6 (7.0) 67. (.6) 0 (0) 509 (3) (.0,.0) Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Notes are at the end of etable, on page 0. USA/Canada/Puert o Rico/US Virgin Islands Total participants Mean (SD) BMI Mean (SD) age at survey Mean (SD) age at death Popln. register measured (5.9) 66. (7.6) 7.0 (.0) 395 (53) 96 () 99.7 (3.9, 5.6) Subtotal ( studies) (.6) 55.7 (9.3) 7.9 (.9) 5336 (39.0) 7335 (.) 9* 5.6 (.9, 6.5) No (%) males No (%) current smokers Median baseline survey year Median (IQR) follow-up time Death ascertain ment All-cause mortality CVD Number of deaths CHD Stroke Cancer Respiratory disease 7

9 etable (continued) Study Ref Country Population source Weight & height Total Mean (SD) Mean (SD) Mean (SD) No (%) assessment participants BMI age at survey age at males death Australia/New Zealand 5 and Up Study 9 Australia General popln. self-reported 63 7 (.9) 6 () 6.5 (0.7) 500 (7) 775 (7.3) (5.7, 6.3) Abdominal Aortic Aneurysm Screening Program 0 Australia Electoral roll measured (3.7) 7. (.) 76.0 (5.0) 90 (00) 330 () (.7, 3.6) Australian Diabetes, Obesity and Lifestyle Study Australia Census list measured (5.0) 5.3 (3.9) 7.0 (.0) 6 (5) 75 (7) (., 3.) Australian Longitudinal Study of Ageing Australia Electoral roll measured 7 6. (.) 77.3 (5.7).0 (6.0) 77 (5) 5 () (.0, 7.9) Busselton Health Study 3 Australia Electoral roll measured 60. (3.) 6.6 (6.) 7.0 (.0) 37 (7) 6 (3) 969. (., 3.7) Dubbo Study of the Elderly Australia Electoral roll measured (.) 69. (6.9) 0.0 (.0) 5 () 6 (5) 99. (.3,.5) Health in Men Study 5 Australia Electoral roll measured (3.7) 7. (.).0 (5.0) 90 (00) 33 () (.3, 3.3) National Heart Foundation Risk Factor Prevalence Survey 99 6 Australia Electoral roll measured (.3) 3. (3.5) 6.0 (.0) 5 (9) 30 () 99.3 (.,.5) Newcastle Study 7 Australia Electoral roll measured (.5) 5.7 (0.5) 65.0 (.0) 9 (50) 36 (3) 9.9 (3.5,.3) Perth Risk Factors Survey Australia Electoral roll measured 0 5. (3.9) 5. (.9) 69.0 (.0) 5 (5) 603 (5) 9.5 (.5, 9.5) Melbourne Collaborative Cohort Study 9 Australia/New Zealand/Europe Electoral roll measured (.) 55. (.7) 7. (.) 696 () 663 () (.0, 6.0) Fletcher Challenge Heart and Health Study 6 New Zealand Electoral roll measured (.). (.9) 69.0 (6.0) 79 (7) 3 () (5., 6.) Subtotal ( studies) (.) 55.6 (0.3) 73.9 (9.3) 666 (50.7) 3077 (0.3) 99-3*.0 (7.,.) No (%) current smokers Median baseline survey year Median (IQR) follow-up time Death ascertain ment All-cause mortality CVD Number of deaths CHD Stroke Cancer Respiratory disease East Asia Anzhen 0 Cohort Study 7 China General popln. measured 5.0 (3.3) 7.0 (.) 53.0 (7.0) 03 (9) 6 () (3.0, 3.0) Beijing Anzhen Cohort Study 7 China General popln. measured (3.7) 53.7 (.7) 7.0 (.0) 37 (5) 377 (9) 99.3 (.3,.3) Beijing Aging Study 30 China General popln. measured (3.9) 69.5 (.3) 77.0 (.0) 05 (9) 6 (30) 99. (.7,.9) Capital Iron & Steel Company Study 3 China Occupational measured (.7) 5.3 (7.9) 59.0 (9.0) 509 (00) 3666 (7) 90.5 (.5, 3.5) Capital Iron & Steel Company Hospital Cohort 7 China Occupational measured 65.7 (3.5). (7.) 9.0 (.0) 06 (9) 59 (7) (3., 3.) China Hypertension Survey Epidemiology Follow-up Study 3 China General popln. measured 97.7 (3.6) 55. (0.6) 70.6 (0.9) (9) 5000 (35) 99. (.,.3) China Prospective Study 33 China Popln. register measured 76.7 (.7) 5.7 (0.) 69.3 (0.) 76 (00) 5990 (67) 99. (9.,.) East Beijing Cohort Study 7 China General popln. measured (3.) 3. (.9) 7.0 (3.0) 5 (9) 30 (30) (9.3, 7.5) Fangshan Cohort Study 3 China Census list measured 606. (3.6) 7.3 (0.0) 6.0 (.0) 7 (33) 0 (39) (.7, 3.7) Huashan Study 7 China Census/electoral roll measured 5 3. (3.) 53.0 (.6) 66.0 (.0) 9 () 60 (5) 99. (.7, 3.0) Nutrition Intervention Trials - Linxian 35 China General popln. measured (.5) 5.9 (.9) 69.5 (.) 33 (5) 39 (30) 95.7 (.6,.7) NA NA NA NA NA Seven Cities Cohort Study 7 China General popln. measured (3.6) 53.7 (.0) 70.0 (0.0) 77 (6) 3757 (35) 97.7 (.7, 0.5) Shanghai Cohort Study 36 China General popln. self-reported 066. (3.0) 55.3 (5.7) 69.3 (7.0) 07 (00) 90 (5) 9.0 (6.,.7) Shanghai Men s Health Study 37 China General popln. measured (3.) 55.3 (9.7) 66.3 (9.) 6339 (00) 359 (59) (.,.) Shanghai Women s Health Study 3 China Popln. register measured 7.0 (3.) 5.6 (9.) 66. (.) 0 (0) 77 () 99.7 (7.9, 9.) Six Chinese Cohorts Study 7 China Occupational measured 93. (.6).7 (7.0) 55.0 (.0) 03 (53) 900 (6) (., 9.) Tianjin Study 39 China NA measured (3.9) 5. (.9) 70.0 (.0) 507 (9) 69 (5) 9 6. (6., 6.) Yunnan Tin Miner Cohort Study 0 China Occupational measured (.9) 55. (9.3) 66.0 (.0) 636 (97) 39 (6) 99.5 (.,.7) Guangzhou Occupational Cohort Study Hong Kong Occupational measured (3.0). (6.) 5.0 (.0) 09 (6) 9907 () (6.7,.6) Hong Kong Study Hong Kong Health insurance list measured 50. (3.7) 76.9 (5.).0 (6.0) 07 () (9) 99.5 (.5, 3.3) Aito Town Study 7 Japan General popln. measured 70.6 (3.0) 5.0 (9.) 69.0 (9.0) 70 (3) 30 () 9 5. (5.0, 6.) Notes are at the end of etable, on page 0.

10 etable (continued) Study Ref Country Population source Weight & height assessment Total participants Mean (SD) BMI Mean (SD) age at survey Mean (SD) age at death Akabane Study 7 Japan General popln. measured 3.5 (3.0) 5. (7.) 6.0 (.0) () 5 () 95.0 (0.7,.6) Civil Service Workers Study 3 Japan Occupational measured 93.5 (.7) 6.7 (.6) 5.0 (.0) 6 (67) 3500 (3) (6.6, 6.) NA 9 60 Funagata Study Japan General popln. measured (3.) 56.6 (.5) 75.0 (0.0) 6 () 33 (9) 99. (7.3,.0) Hisayama Study 5 Japan Popln. screening measured 5.6 (.7) 55.9 (0.9) 75.0 (0.0) 665 () 65 (3) 96.6 (.6, 5.) Ibaraki Prefectural Health Study 6 Japan General popln. measured (3.) 5. (0.) 75.0 (.5) 333 (3) 959 (0) (.,.5) NA NA NA NA NA Ikawa, Kyowa, Noichi Study 7 Japan Popln. screening measured 3.6 (3.) 5. (.) 69.0 (9.0) 95 () 6 (3) (5.5,.5) Japan Collaborative Cohort Study Japan General popln. self-reported 650. (3.0) 57.6 (0.0) 7. (9.) 3605 () 069 () 99.3 (0., 5.0) Japan Public Health Center based Residential 9 Japan Prospective Study registry self-reported (3.0) 9.6 (5.9) 6.6 (7.0) 057 () () (5., 5.9) Japan Public Health Center based Residential 9 Japan Prospective Study registry self-reported (3.) 5. (.) 67. (.3) 60 (7) 53 () 993. (.9,.9) Japan Railways 50 Japan Occupational measured (.). (7.5) 53.0 (5.0) 595 (00) 7 (50) (.5, 0.5) Konan Health and Nutrition Study 7 Japan General popln. measured.9 (3.0) 5.6 (5.7) 7.0 (3.0) 53 (5) 359 (30) (.,.) Kyowa Study 7 Japan Popln. screening measured (3.) 53.9 (.5) 67.0 (.0) 6 (3) 36 (33) (.5,.5) Life Span Study Cohort 5 Japan General popln. self-reported 95.0 (3.) 5.0 (3.) 7. (.) 9607 (0) 9 (39) (.0, 3.) Miyagi Cohort 5 Japan Residential registry self-reported (3.0) 5.9 (7.5) 6.7 (7.6) 97 () 5 (3) (3.6, 3.6) Miyama Cohort Study 53 Japan Popln. register measured 03. (.9) 60. (9.5) 7.0 (.0) 6 (5) 305 (30) (6., 6.7) Noichi Study 7 Japan Popln. screening measured 6.9 (3.) 53. (9.) 7.0 (9.0) (37) 5 (6) (.5,.5) Ohasama Study 5 Japan General popln. measured (3.) 57. (.) 7.0 (.0) 3 (39) 677 () (.5, 5.5) Ohsaki National Health Insurance Cohort Health insurance 55 Japan self-reported 3.5 (3.) 60. (0.) 73.9 (9.0) 97 () 36 (9) (9.,.0) + Study list Osaka Study 56 Japan Popln. register measured (.) 5.5 (9.7) 7.0 (.0) 5 (6) 60 (39) (6.5, 6.) Oyabe study 57 Japan Popln. screening measured (.9) 56.9 (.) 75.0 (0.0) 60 (3) 9 (9) 9 0. (0.3, 0.5) Saitama Cohort Study 5 Japan General popln. measured 359. (.9) 5.5 (.) 7.0 (0.0) 363 (3) 0 (9) 97.0 (9.0,.0) Seven Countries Japan Japan General popln. measured (.) 9. (5.7) 67.0 (.0) 960 (00) 700 (73) 95.5 (6.5,.5) Shibata Cohort Study 59 Japan General popln. measured 3. (3.0) 56.7 (.) 76.0 (0.0) 9 () 770 (33) (.6, 0.0) Shigaraki Town Study 60 Japan General popln. measured 37.5 (3.) 57. (3.9) 76.0 (.0) 56 () 063 (9) 993. (., 5.) Shirakawa Study 7 Japan General popln. measured (.).0 (.3) 67.0 (0.0) (6) 67 (35) (5.5,.5) Tanno - Soubetsu Study 6 Japan General popln. measured (3.) 5. (6.9) 66.0 (.0) 930 (7) 76 (39) (6., 7.) NA Three Prefecture Study Aichi 6 Japan Residential self-reported registry 305. (.9) 56.0 (.) 75.6 (.) 503 (7) 0099 (3) (7.7, 5.5) Three Prefecture Study Miyagi 6 Japan Residential registry self-reported (3.) 56.7 (.0) 75.6 (0.9) 360 (5) 65 () (.0, 5.0) Toyama Study 63 Japan Occupational measured 5 3. (3.0) 5.6 (6.6) 73.0 (.0) 907 (6) 75 (39) (.7,.) Singapore Chinese Health Study 6 Singapore Household listings self-reported (3.) 56.5 (.0) 69. (.) 77 () 77 (9) 99. (9., 3.) Singapore Thyroid and Heart Study 65 Singapore Census list measured (.3) 0.7 (3.) 66.0 (.0) 75 (5) 507 () 9.6 (.7, 5.5) Singapore National Health Survey Singapore General popln. measured (.) 39. (.5) 57.0 (3.0) 59 () 60 () (6., 6.3) Korean Cancer Prevention Study 67 South Korea Health insurance list measured (.) 50.0 (0.) 70. (.) 6775 (6) 03 (37) 99.0 (7.3, 9.0) Korean Medical Insurance Corporation Health insurance 6 South Korea Study list measured (.5). (6.7) 5.0 (7.0) 557 (63) 65 (3) 99.0 (.0,.0) Korean Multi-center Cancer Cohort Study 69 South Korea Popln. screening measured (3.) 55.6 (.) 7. (0.) 63 (0) 0 (6) (3.5, 9.3) No (%) males No (%) current smokers Median baseline survey year Median (IQR) follow-up time Death ascertain ment All-cause mortality CVD Number of deaths CHD Stroke Cancer Respiratory disease Seoul Male Cancer Cohort 70 South Korea Health insurance list self-reported (.3) 9. (5.) 60. (6.) 395 (00) 696 (50) (.9, 5.) Notes are at the end of etable, on page 0. 9

11 etable (continued) Study Ref Country Population source Weight & height assessment Total participants Mean (SD) BMI Mean (SD) age at survey Mean (SD) age at death Cardiovascular Disease Risk Factors Two- Township Study 7 Taiwan General popln. measured (3.5). (5.) 73. (.9) 0 () 6 () (.9, 6.7) Community-based Cancer Screening Project 7 Taiwan General popln. measured (3.) 7.3 (0.0) 6.3 (9.) 939 (50) 600 (5) (5.5, 6.3) The Kinmen Neurological Disorders Survey 73 Taiwan General popln. measured 6 3. (3.) 6.7 (9.) 77.0 (0.0) 669 (53) 353 (30) 99.9 (.,.9) Electrical Generating Authority of Thailand Study 7 Thailand Occupational measured (3.) 3.0 (5.) 53.0 (6.0) 697 (77) 509 (3) 95. (.,.) Subtotal (6 studies) (3.) 5. (9.6) 67. (9.) (60.0) (36.7) 990* 3.9 (.,.) No (%) males No (%) current smokers Median baseline survey year Median (IQR) follow-up time Death ascertain ment All-cause mortality CVD Number of deaths CHD Stroke Cancer Respiratory disease South Asia Health Effects of Arsenic Longitudinal Study 75 Bangladesh General popln. measured (3.) 37. (9.9) 5.6 (.0) 79 (3) 39 (9) (6., 7.) Mumbai Cohort Study 76 India Electoral roll measured 3.5 (.0) 50.6 (.0) 65.0 (.0) 5576 (60) 6 (5) (5., 6.) Trivandrum Oral Cancer Screening Trial 77 India General popln. measured (3.9) 9.3 (.) 67.3 (.) 66 (39) 7597 () 997. (5., 9.) Subtotal (3 studies) 0.5 (3.7) 5.7 (.0) 6.3 (.) 390 (50) 56 (9) 997* 6.9 (5.5, 7.5) TOTAL (39 studies) (3.9) 53. (.9) 6.5 (.6) 5709 (3.) 759 (6) 99* 3.7 (.,.7) Data are for participants with BMI 5 or 60kg/m, or with a baseline age 0 or 9 years. Inverse probability sampling weights were used to account for the complex survey study design of the National Health and Nutrition Examination Survey I and III and the National Health Interview Survey. Ref = reference number in the list of references in eappendix 5. NA: Not available. Death ascertainment method: +, Death certificate only; ++, Death certificate supplemented by medical record. ** EPIC participants were recruited from the general population of their respective countries, with the following exceptions: the French cohort was occupational; the Italian and Spanish studies included members of blood donor associations and the general population; the Utrecht (the Netherlands) and Florence (Italy) studies were from population screening; the Oxford UK study included many vegetarians, vegans, and low meat eaters; and the studies in France, Norway, Naples (Italy) and Utrecht (the Netherlands) included only women. Analysis omitted data on 96 participants from two studies that each recorded fewer than 0 deaths, so a total of deaths were omitted from the Capital Iron & Steel Company Hospital Cohort and the Risk Factors and Life Expectancy Pooling Project (GREPCO). * For subtotals and for the total (all studies), the table gives the median of the study-specific median baseline survey year; for all 39 studies this is 99 (IQR ) 0

12 etable : Chronic diseases recorded in each participating study at baseline examination Study Ref Country Heart disease Stroke Other vascular disease Cancer Respiratory diseases Europe Vorarlberg Health Monitoring and Promotion Programme Austria Belgian Inter-university Research on Nutrition and Health Belgium Flemish Study on Environment Genes and Health (FLEMENGHO) 3 Belgium Seven Countries Croatia Croatia Copenhagen City Heart Study 5 Denmark Research Centre for Prevention and Health (Glostrup Population Studies) 6 Denmark Finnish Mobile Clinic Survey 7 Finland Finrisk Cohort 977 Finland Finrisk Cohort 9 Finland Finrisk Cohort 97 Finland Finrisk Cohort 99 Finland Finrisk Cohort 997 Finland Helsinki Aging Study 9 Finland Helsinki Businessmen Study 0 Finland Kuopio Ischaemic Heart Disease Study Finland North Karelia Project Finland Seven Countries Finland Finland Centre d'investigations Preventives et Cliniques (IPC) Paris 3 France Data from an Epidemiological Study on the Insulin Resistance Syndrome France Paris Prospective Study I 5 France Prospective Epidemiological Study of Myocardial Infarction 6 France / NI Epidemiologische Studie zu Chancen der Verhütung 7 Germany Göttingen Risk Incidence and Prevalence Study Germany MONICA/KORA Augsburg Survey 9 Germany MONICA/KORA Augsburg Survey 9 Germany MONICA/KORA Augsburg Survey 3 9 Germany Prospective Cardiovascular Münster Study 0 Germany Study of Health in Pomerania Germany Württemberg Construction Workers Cohort Germany ATTICA Study 3 Greece Seven Countries Greece Greece Reykjavik Study Iceland Bezafibrate Infarction Prevention Registry Study 5 Israel Israeli Ischaemic Heart Disease Study 6 Israel Glucose Intolerance Obesity and Hypertension Study 7 Israel Bruneck Study Italy Cardiovascular Study in the Elderly 9 Italy Occupational Groups (OG), Rome 30 Italy Progetto CUORE (ATENA) 3 Italy Progetto CUORE (EMOFRI) 3 Italy Progetto CUORE (MATISS3) 3 Italy Progetto CUORE (MATISS7) 3 Italy Progetto CUORE (MATISS93) 3 Italy Progetto CUORE (MONFRI6) 3 Italy Progetto CUORE (MONFRI9) 3 Italy Progetto CUORE (MONFRI9) 3 Italy Risk Factors and Life Expectancy Pooling Project (ATS_SAR) 3 Italy Risk Factors and Life Expectancy Pooling Project (DISCO) 3 Italy Risk Factors and Life Expectancy Pooling Project (GREPCO) 3 Italy Risk Factors and Life Expectancy Pooling Project (GUBBIO) 3 Italy Risk Factors and Life Expectancy Pooling Project (MICOL) 3 Italy Risk Factors and Life Expectancy Pooling Project (MONICA) 3 Italy Risk Factors and Life Expectancy Pooling Project (NFR) 3 Italy Risk Factors and Life Expectancy Pooling Project (OB3) 3 Italy Risk Factors and Life Expectancy Pooling Project (RF) 3 Italy Seven Countries Italy Italy Vicenza Thrombophilia and Athrosclerosis Project 33 Italy Consultation Bureau Project 3 Netherlands Hoorn Study 35 Netherlands Longitudinal Aging Study Amsterdam 36 Netherlands Ref = reference number in the list of references in eappendix 5.

13 etable (continued) Study Ref Country Heart disease Stroke Other vascular disease Cancer Respiratory diseases Monitoring of CVD Risk Factors Project 37 Netherlands Prevention of Renal and Vascular End Stage Disease Study 3 Netherlands Seven Countries Netherlands Netherlands The Rotterdam Study 39 Netherlands The Rotterdam Study II 39 Netherlands The Rotterdam Study III 39 Netherlands Cohort of Norway (FINNMARK) 0 Norway Cohort of Norway (HUBRO) 0 Norway Cohort of Norway (OPPHED) 0 Norway Cohort of Norway (OSLO) 0 Norway Cohort of Norway (TROMS) 0 Norway Norwegian Counties Study (NCS) Norway Norwegian Counties Study (NCS) Norway Norwegian Counties Study (NCS3) Norway Oslo Study Norway Tromsø Study 3 Norway Edinburgh Artery Study Scotland Prospective Study of Pravastatin in the Elderly at Risk 5 Scotland/Ireland/Net herland Seven Countries Serbia Serbia Diet and Risk of Cardiovascular Disease in Spain 6 Spain Zaragoza study 7 Spain Apolipoprotein Related Mortality Risk Study Sweden Cohort of Swedish Men 9 Sweden Göteborg 93 Study 50 Sweden Göteborg 933 Study 50 Sweden Göteborg 93 Study 50 Sweden MONICA Göteborg Study 9 Sweden Malmö Prevention Project 5 Sweden Prospective Study of Women in Gothenburg 5 Sweden Swedish Mammography Cohort 53 Sweden Uppsala Longitudinal Study of Adult Men 5 Sweden Women's Lifestyle and Health Study 55 Sweden Turkish Adult Risk Factor Study 56 Turkey British Regional Heart Study 57 UK British Union Provident Association Study 5 UK British Women's Heart and Health Study 59 UK Caerphilly Prospective Study 60 UK Hertfordshire Cohort Study 6 UK Lower Extremity Arterial Disease Event Reduction Trial 6 UK Midspan Family Study 63 UK The Million Women Study 6 UK MRC Study of Older People 65 UK Midspan Collaborative Study 66 UK Northwick Park Heart Study I 66 UK Northwick Park Heart Study II 67 UK Renfew and Paisley Study 6 UK Scottish Heart Health Study 60 UK Speedwell Study 69 UK Thrombosis Prevention Trial 70 UK UK Biobank 7 UK United Kingdom Heart Disease Prevention Project 7 UK West of Scotland Coronary Prevention Study 73 UK Whitehall I Study 7 UK Whitehall II Study 75 UK European Prospective Investigation into Cancer and Nutrition 76 Europe North America Nova Scotia Health Survey 77 Canada Quebec Cardiovascular Study 7 Canada Agricultural Health Study 79 USA Air Force/Texas Coronary Atherosclerosis Prevention Study 0 USA NIH-AARP Diet and Health USA Ref = reference number in the list of references in eappendix 5.

14 etable (continued) Study Ref Country Heart disease Stroke Other vascular disease Cancer Respiratory diseases Atherosclerosis Risk in Communities Study USA Breast Cancer Detection Demonstration Project 3 USA CLUE II USA California Teachers Study 5 USA Cancer Prevention Study I 6 USA Cancer Prevention Study II 6 USA Cardiovascular Health Study (CHS) 7 USA Cardiovascular Health Study (CHS) 7 USA Charleston Heart Study USA Chicago Heart Association Detection Project In Industry 9 USA Established Populations for the Epidemiologic Studies of the Elderly - East Boston 90 USA Established Populations for the Epidemiologic Studies of the Elderly - Iowa 90 USA Established Populations for the Epidemiologic Studies of the Elderly - New Haven 90 USA Established Populations for the Epidemiologic Studies of the Elderly - North Carolina 90 USA Framingham Offspring Study 9 USA Health Professionals Follow-up Study 9 USA Honolulu Heart Program 93 USA Iowa Women's Health Study 9 USA Lipid Research Clinics Follow-up Study 95 USA Minnesota Heart Health Project 96 USA Minnesota Heart Survey 97 USA Multi-Ethnic Study of Atherosclerosis 9 USA Multiple Risk Factor Intervention Trial 99 USA NHLBI Framingham Heart Study 00 USA NYU Women's Health Study 0 USA National Health and Nutrition Examination Survey I 0 USA National Health and Nutrition Examination Survey III 03 USA National Health Interview Survey 0 USA Nurses' Health Study I 05 USA Nurses' Health Study II 06 USA Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial 07 USA Physicians' Health Study I & II 0 USA Puerto Rico Heart Health Program 09 USA Rancho Bernardo Study 0 USA Seven Countries US USA Seventh-day Adventist Cohort Study USA Strong Heart Study USA Tecumseh Study 3 USA U.S. Radiologic Technologists (URST) Cohort USA Vitamins and Lifestyle (VITAL) Study 5 USA Women's Health Initiative (Oberservational Study) 6 USA Women's Health Study 7 USA Antihypertensive and Lipid-Lowering Treatment to Prevent Heart USA/Canada/Puerto Rico/US Virgin Attack Trial Islands Australia/New Zealand 5 and Up Study 9 Australia Abdominal Aortic Aneurysm Screening Program 0 Australia Australian Diabetes, Obesity and Lifestyle Study Australia Australian Longitudinal Study of Ageing Australia Busselton Health Study 3 Australia Dubbo Study of the Elderly Australia Health in Men Study 5 Australia National Heart Foundation Risk Factor Prevalence Survey 99 6 Australia Newcastle Study 7 Australia Perth Risk Factors Survey Australia Melbourne Collaborative Cohort Study 9 Australia/New Zealand/Europe Fletcher Challenge Heart and Health Study 6 New Zealand East Asia Anzhen 0 Cohort Study 7 China Beijing Anzhen Cohort Study 7 China Beijing Aging Study 30 China Capital Iron & Steel Company Study 3 China Capital Iron & Steel Company Hospital Cohort 7 China China Hypertension Survey Epidemiology Follow-up Study 3 China China Prospective Study 33 China East Beijing Cohort Study 7 China Ref = reference number in the list of references in eappendix 5. 3